An Audit to Verify a Key Performance Indicator: Secondary Prevention Medication Prescription: Registry Versus Real-World Rates Post-Acute Coronary Syndromes

Heart Lung and Circulation - United Kingdom
doi 10.1016/j.hlc.2019.05.055
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Post-Myocardial Infarction (MI) Care: Medication Adherence for Secondary Prevention After MI in a Large Real-World Population

Clinical Therapeutics
Pharmacology
2019English

Current Outcome of Acute Coronary Syndromes: Data From the Zurich-Acute Coronary Syndrome (Z-Acs)-Registry

Cardiovascular Medicine
2013English

Management of Patients With Acute Coronary Syndromes in Real-World Practice in Italy: An Outcome Research Study Focused on the Use of ANTithRombotic Agents: The MANTRA Registry

European Heart Journal: Acute Cardiovascular Care
Intensive Care MedicineMedicineCritical CareCardiovascular MedicineCardiology
2013English

Pcv40 - Budget Impact Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pcv76 - Cost-Effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Acute Coronary Syndromes

British Medical Journal
Medicine
2015English

Acute Coronary Syndromes

2018English

Evidence of Poor Adherence to Secondary Prevention After Acute Coronary Syndromes: Possible Remedies Through the Application of New Technologies

Open Heart
Cardiovascular MedicineCardiology
2015English

Acute Coronary Syndromes

JAMA - Journal of the American Medical Association
Medicine
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy